G1 Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

G1 Therapeutics

30/10/2023 18:33

* G1 Therapeutics Inc  GTHX.OQ   GTHX.O  is expected to show
a
fall in quarterly revenue when it reports  results 
    * The Research Triangle Park North Carolina-based  company
is
expected to report  a 39.6% decrease in revenue to $14.229
million from $23.58 million a year ago, according to the mean
estimate from 6 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for G1 Therapeutics Inc
is
for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $9.5​, above​ its last closing price of $1.52. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.22      0.14      Beat    164
 Mar. 31 2023  -0.62       -0.64      -0.53     Beat    17.2
 Dec. 31 2022  -0.84       -0.84      -0.73     Beat    13.5​
 Sep. 30 2022  -0.61       -0.63      -0.59     Beat    6.7
 ​​Jun.        -1.02       -1.02      -0.92     Beat    9.7
 30 2022                                                
 Mar. 31 2022  -0.97       -0.97      -1.15     Missed  -18​
 Dec. 31 2021  -1.03       -1.03      -0.94     Beat    9.2
 Sep. 30 2021  -1.01       -1.01      -1.00     Beat    0.5
 This summary was machine generated October 30 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated